Home › Funds › Cormorant Asset Management, LP › AGMB
Cormorant Asset Management, LP position in AGMB
AGOMAB THERAPEUTICS NV · Health Care
Cormorant Asset Management, LP reported holding 2,465,348 shares of AGMB (AGOMAB THERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$32.0M, representing 1.64% of its reported portfolio and ranking #19 among its reported holdings. Cormorant Asset Management, LP has disclosed AGMB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's AGMB position evolved
Cormorant Asset Management, LP first disclosed a stake in AGMB in Q1 2026 at 2,465,348 shares (US$25.9M). The position peaked in Q2 2026 at 2,465,348 shares, worth US$32.0M. Across 2 filings, Cormorant Asset Management, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,465,348 shares valued at US$32.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 2.47M | $25.86M | New |
| Q2 2026 | 2.47M | $32.00M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGMB and 13F data
AGMB (AGOMAB THERAPEUTICS NV) is a Health Care company. 33 other funds we track also report a position in AGMB — the largest reported positions include EQT Fund Management S.a r.l. (US$66.7M), Sanofi (US$36.1M), Redmile Group, LLC (US$35.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGMB
- EQT Fund Management S.a r.l. 5.14M sh · $66.74M · Q2 2026
- Sanofi 2.78M sh · $36.12M · Q2 2026
- Redmile Group, LLC 2.73M sh · $35.49M · Q2 2026
- TCG Crossover Management, LLC 2.05M sh · $26.65M · Q2 2026
- Nantahala Capital Management, LLC 1.57M sh · $20.36M · Q2 2026
- Casdin Capital 1.55M sh · $20.12M · Q2 2026
- Andera Partners 1.54M sh · $17.08M · Q3 2026
- Samsara BioCapital, LLC 600.00K sh · $7.79M · Q2 2026
- PFIZER INC 75.00K sh · $1.04M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held AGMB?
Cormorant Asset Management, LP has disclosed AGMB holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Cormorant Asset Management, LP's current position in AGMB?
As of Q2 2026, Cormorant Asset Management, LP holds 2.47M shares of AGMB (AGOMAB THERAPEUTICS NV), valued at $32.00M, representing 1.64% of its reported portfolio and ranking #19.
Has Cormorant Asset Management, LP been buying or selling AGMB?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP held unchanged its position in AGMB. The position peaked in Q2 2026 at 2.47M shares.
Which other funds hold AGMB?
Other major institutional holders of AGMB include EQT Fund Management S.a r.l., Sanofi, Redmile Group, LLC, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.